Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab

  • Ian L. P. BealesEmail author

Dear Editor

The report by Grandinetti and colleagues showing that vedolizumab may be an effective rescue therapy for eosinophilic gastroenteritis [1] should stimulate further interest and exploration of the leukocyte-trafficking inhibitors in gastrointestinal inflammatory diseases, including those such as eosinophilic gastroenteritis where the dominant inflammatory cells are not lymphocytes (which are of course the classical target of the α4β7 integrin inhibitors [2]). Indeed another small series has also reported efficacy of vedolizumab as rescue therapy in some cases of refractory eosinophilic gastroenteritis [3]. Eosinophilic esophagitis (EoE) is part of the spectrum of eosinophilic GI disease, although as Grandinetti et al. describe, the esophagus can be involved in the more classical pan-enteric disease form, but isolated EoE is probably a more specific localized disease with individual etiology and treatment strategies [4]. Neither of those two recent reports examined the effect...



  1. 1.
    Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab. Dig Dis Sci. (Epub ahead of print).
  2. 2.
    Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an alpha4beta7 integrin antagonist for ulcerative colitis and Crohn’s disease. Ther Adv Chronic Dis. 2015;6:224–233.CrossRefGoogle Scholar
  3. 3.
    Kim HP, Reed CC, Herfarth HH, Dellon ES. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018;16:1992–1994.CrossRefGoogle Scholar
  4. 4.
    Schoepfer A, Blanchard C, Dawson H, et al. Eosinophilic esophagitis: latest insights from diagnosis to therapy. Ann N Y Acad Sci. 2018;1434:84–93.CrossRefGoogle Scholar
  5. 5.
    Taft TH, Mutlu EA. The potential role of vedolizumab in concomitant eosinophilic esophagitis and Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16:1840–1841.CrossRefGoogle Scholar
  6. 6.
    Rice GPA, Hartung H-P, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis. Mech Ration. 2005;64:1336–1342.Google Scholar
  7. 7.
    Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;9:CD011381.Google Scholar
  8. 8.
    MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;1:CD006097.Google Scholar
  9. 9.
    Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–933.CrossRefGoogle Scholar
  10. 10.
    Brandt EB, Zimmermann N, Muntel EE, et al. The alpha4beta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2006;36:543–553.CrossRefGoogle Scholar
  11. 11.
    Rieder F, Nonevski I, Ma J, et al. T-helper 2 cytokines, transforming growth factor β1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis. Gastroenterology. 2014;146:1266–1277.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyNorfolk and Norwich University HospitalNorwichUK

Personalised recommendations